74.33 USD
▲+5.27+7.63%
盘后 74.07 -0.35%
2026-11-19
市值
$1.02B
市盈率
—
EPS
-9.06
股息率
—
52 周区间
57.30 – 155.29
成交量
420.89K
Beta
4.04
目标价
258.33
52W 低 57.3052W 高 155.29
价格走势
公司简介
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung canc...